We work with most cell lines used for manufacturing monoclonal antibodies and recombinant proteins, including CHO, NS/0, BHK, 293 as well as murine hybridomas, and all selection systems used with these lines. We have also worked with several different selection systems such as dhfr / methotrexate CHO, mycophenolic acid/xanthine, and G418 systems. Our experience includes attached or surface dependent as well as suspension culture types.
While we are proud of what we do, we know we can't do it all. That's why we've selectively collaborated with companies that complement our skill sets.
ImmunoSite Technologies
Formed in 2009 as a spin-off of Beckman Coulter, Inc., ImmunoSite Technologies, LLC (IST) offers a full range of contract research (CRO) for immune monitoring, particle testing, and process automation services for biotechnology, pharmaceutical, manufacturing and academic organizations around the world. Fully GLP compliant and based in Fort Lauderdale, Fla., IST’s team has 110 years of rigorous product development experience, has been published over 300 peer-reviewed scientific publications, has authored over 30 U.S. and international patents, and has developed and successfully commercialized over 200 diagnostic (IVD) product reagents, kits and instrument systems. IST is distinguished by its ongoing partnerships with best-in-class clinical trial organizations such as: the Immune Tolerance Network, the Immune Tolerance Institute, and the Imperial College of London-managed CD4 Initiative. This extensive immune monitoring and cell analysis R&D experience qualifies IST scientists to accelerate vaccine, biologic and drug discovery, and to comply with complex and demanding international scientific and governmental regulations.
For more information on the collaboration, please click here
Macrocyclics
As the established global leader in high performance chelating agent technologies for medicine since 1995, the team at Macrocyclics is dedicated to providing clients with innovative and customized chelating agents and being on the leading-edge of developing new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine. Their chelating agent products and services meet the challenges of molecular imaging and nuclear medicine. From basic research to early stage clinical development, Macrocyclics combines an extensive background in chelation chemistry with expertise in medical imaging that can help to meet your goals.
Rafagen
RAFAGEN's primary focus is on the development and commercialization of next generation gene expression systems, with applications in solving the most challenging problems in molecular therapeutics. RAFAGEN will leverage its core technology to build up a strategic framework for revenue generation in licensing deals and service contracts, and eventually, for its own development of highly effective molecular therapy drugs.
In the field of recombinant protein and monoclonal antibody therapeutics, RAFAGEN's technology facilitates a marked increase in drug production from manufacturing facilities. Protein drugs will be launched in the market and revenue will be generated at a faster rate than ever before. In this rapidly emerging and highly competitive market, companies applying RAFAGEN's state-of-art technologies will amass unparalleled selective advantages.
CTO Testing
In order to ensure product purity and integrity, extensive testing is required for each stage of the manufacturing process. GBI offers a panel of qualified assays readily available to expedite product and process development. GBI can also accommodate specific assays transferred from clients and can develop and qualify these assays in accordance with regulatory requirements. Assays that cannot be accommodated using GBI equipment or those that would not be compatible with GBI's facilities (such as viral testing) are contracted to qualified outside vendors.
